These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

419 related items for PubMed ID: 9162613

  • 1. Effect of combination therapy of troglitazone and sulphonylureas in patients with Type 2 diabetes who were poorly controlled by sulphonylurea therapy alone.
    Iwamoto Y, Kosaka K, Kuzuya T, Akanuma Y, Shigeta Y, Kaneko T.
    Diabet Med; 1996 Apr; 13(4):365-70. PubMed ID: 9162613
    [Abstract] [Full Text] [Related]

  • 2. Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients.
    Kumar S, Prange A, Schulze J, Lettis S, Barnett AH.
    Diabet Med; 1998 Sep; 15(9):772-9. PubMed ID: 9737807
    [Abstract] [Full Text] [Related]

  • 3. Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy--a randomized controlled trial.
    Katoh S, Hata S, Matsushima M, Ikemoto S, Inoue Y, Yokoyama J, Tajima N.
    Metabolism; 2001 Apr; 50(4):414-7. PubMed ID: 11288035
    [Abstract] [Full Text] [Related]

  • 4. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes.
    Sironi AM, Vichi S, Gastaldelli A, Pecori N, Anichini R, Foot E, Seghieri G, Ferrannini E.
    Clin Pharmacol Ther; 1997 Aug; 62(2):194-202. PubMed ID: 9284856
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P, Sitagliptin Study 035 Group.
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P, Sitagliptin Study 019 Group.
    Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
    [Abstract] [Full Text] [Related]

  • 7. Results of a randomized, double-blind, placebo-controlled study administering glimepiride to patients with type 2 diabetes mellitus inadequately controlled with rosiglitazone monotherapy.
    McCluskey D, Touger MS, Melis R, Schleusener DS, McCluskey D.
    Clin Ther; 2004 Nov; 26(11):1783-90. PubMed ID: 15639690
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.
    Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, Shulman GI.
    N Engl J Med; 1998 Mar 26; 338(13):867-72. PubMed ID: 9516221
    [Abstract] [Full Text] [Related]

  • 9. Sustained-release versus immediate-release glipizide for treatment of type 2 diabetes mellitus in chinese patients: A randomized, double-blind, double-dummy, parallel-group, 12-week clinical study.
    Hsieh SH, Lin JD, Cheng HY, Ho C, Liou MJ.
    Clin Ther; 2006 Sep 26; 28(9):1318-26. PubMed ID: 17062305
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy.
    Rosenstock J, Einhorn D, Hershon K, Glazer NB, Yu S, Pioglitazone 014 Study Group.
    Int J Clin Pract; 2002 May 26; 56(4):251-7. PubMed ID: 12074206
    [Abstract] [Full Text] [Related]

  • 11. Combination-therapy with bedtime nph insulin and sulphonylureas gives similar glycaemic control but lower weight gain than insulin twice daily in patients with type 2 diabetes.
    Olsson PO, Lindström T.
    Diabetes Metab; 2002 Sep 26; 28(4 Pt 1):272-7. PubMed ID: 12442064
    [Abstract] [Full Text] [Related]

  • 12. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial.
    Yale JF, Valiquett TR, Ghazzi MN, Owens-Grillo JK, Whitcomb RW, Foyt HL.
    Ann Intern Med; 2001 May 01; 134(9 Pt 1):737-45. PubMed ID: 11329231
    [Abstract] [Full Text] [Related]

  • 13. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
    Derosa G, D'Angelo A, Salvadeo SA, Ferrari I, Gravina A, Fogari E, Maffioli P, Cicero AF.
    Metabolism; 2008 Nov 01; 57(11):1552-7. PubMed ID: 18940393
    [Abstract] [Full Text] [Related]

  • 14. Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy.
    Iwamoto Y, Kosaka K, Kuzuya T, Akanuma Y, Shigeta Y, Kaneko T.
    Diabetes Care; 1996 Feb 01; 19(2):151-6. PubMed ID: 8718436
    [Abstract] [Full Text] [Related]

  • 15. Troglitazone in combination with sulphonylurea improves glycaemic control in Type 2 diabetic patients inadequately controlled by sulphonylurea therapy alone. Troglitazone Study Group.
    Buysschaert M, Bobbioni E, Starkie M, Frith L.
    Diabet Med; 1999 Feb 01; 16(2):147-53. PubMed ID: 10229309
    [Abstract] [Full Text] [Related]

  • 16. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.
    Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J.
    N Engl J Med; 1994 Nov 03; 331(18):1188-93. PubMed ID: 7935656
    [Abstract] [Full Text] [Related]

  • 17. [The efficacy and safety of pioglitazone hydrochloride in combination with sulphonylureas and metfomin in the treatment of type 2 diabetes mellitus a 12-week randomized multi-centres placebo-controlled parallel study].
    Pan C, Gao Y, Gao X, Li G, Luo B, Shi H, Tian H, Jia P, Lin H, Xing X, Zhao Y, Zhou L.
    Zhonghua Nei Ke Za Zhi; 2002 Jun 03; 41(6):388-92. PubMed ID: 12137601
    [Abstract] [Full Text] [Related]

  • 18. Pharmacological regulation of blood glucose levels in non-insulin-dependent diabetes mellitus.
    Bressler R, Johnson DG.
    Arch Intern Med; 1997 Apr 28; 157(8):836-48. PubMed ID: 9129543
    [Abstract] [Full Text] [Related]

  • 19. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group.
    Kumar S, Boulton AJ, Beck-Nielsen H, Berthezene F, Muggeo M, Persson B, Spinas GA, Donoghue S, Lettis S, Stewart-Long P.
    Diabetologia; 1996 Jun 28; 39(6):701-9. PubMed ID: 8781766
    [Abstract] [Full Text] [Related]

  • 20. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives.
    Ogihara T, Rakugi H, Ikegami H, Mikami H, Masuo K.
    Am J Hypertens; 1995 Mar 28; 8(3):316-20. PubMed ID: 7794582
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.